Tumor mutational burden (TMB) is a key factor in determining the response of patients with cancer to immunotherapy with immune checkpoint inhibitors (anti-programmed cell death 1 [PD-1] or anti-cytotoxic T lymphocyte-associated antigen 4 [CTLA-4]) (2–7). This evidence concerns the gene PDCD1 and neoplasm.